Abstract: A graphical user interface for a medical system comprises a display device, an electronic processor that operates with the display device to display a plurality of screens including a programming screen by which a user can enter or modify medical treatment parameters employed by a machine to perform a medical treatment. When a user modifies a first medical treatment parameter, the processor is programmed to adjust at least one other medical treatment parameters depending on the first medical treatment parameters.

Abstract: Disclosed herein are pressure control systems, comprising: a touch screen electrically connected to industrial computer or embedded operating system; a pressure output channel connected to the touch screen and/or the industrial computer or embedded operating system; and pressure control unit for communicating with the pressure output channel, wherein the pressure control unit can be controlled with the touch screen, and wherein the industrial computer or embedded operating system comprises preinstalled software with User Interface (UI) for pressure control setup and running the system.

Abstract: Nanodiamond particles and related devices and methods, such as nanodiamond particles for the detection and/or quantification of analytes, are generally described. In some embodiments, the device comprises a plurality of nanodiamond particles and a species bound to the nanodiamond particles. In certain embodiments, the plurality of nanodiamond particles may be exposed to a sample suspected of containing an analyte. In some cases, the analyte may bind to the species such that the presence of the analyte in the sample may be detected. In some embodiments, the devices, systems, and methods described herein are useful for the detection of an analyte in a sample obtained from a subject for, for example, diagnostic purposes. In some cases, the systems, devices, and methods described herein may be useful for diagnosing, prevent, treating, and/or managing a disease or bodily condition.

Abstract: Nanodiamond particles and related devices and methods, such as nanodiamond particles for the detection and/or quantification of analytes, are generally described. In some embodiments, the device comprises a plurality of nanodiamond particles and a species bound to the nanodiamond particles. In certain embodiments, the plurality of nanodiamond particles may be exposed to a sample suspected of containing an analyte. In some cases, the analyte may bind to the species such that the presence of the analyte in the sample may be detected. In some embodiments, the devices, systems, and methods described herein are useful for the detection of an analyte in a sample obtained from a subject for, for example, diagnostic purposes. In some cases, the systems, devices, and methods described herein may be useful for diagnosing, prevent, treating, and/or managing a disease or bodily condition.

Abstract: A purification system and method may include a container receiving portion, pump, and magnetic field generating element. The container receiving portion may be configured to receive and support a container containing a mixture. Magnetic beads may be added to the container for separating a target substance from a remainder of the mixture. The magnetic field generating element may be movable relative to the container receiving portion between a non-working position remote from the container receiving portion and a working position adjacent an outer periphery of the container receiving portion. In the working position, the magnetic field generating element may attract the magnetic beads and hold them firmly against an interior surface of the container. While the magnetic beads are immobilized by the magnetic field generating element, the pump may remove the mixture from the container, leaving behind the magnetic beads bound tightly but reversibly to the target substance.

Abstract: The present invention is a UV light box, systems, and methods for irradiating plasma.

Abstract: Systems and methods for purification and concentration of autologous alpha-2-macroglobulin (A2M) from whole blood are provided. Also provided are diagnostic methods for identifying sites in the synovial joints, spine, tendons or ligaments for treatment of pain, degeneration, or inflammation with autologous A2M. Methods for utilizing autologous A2M in combination with other autologous treatments (e.g. platelets and other growth factors) are provided in addition to combinations with exogenous drugs or carriers. Also provided is a method of producing recombinant A2M wild type or variants thereof where the bait region was modified to enhance the inhibition characteristics of A2M and/or to prolong the half life of the protein in joints and spine disc or epidural space.

Abstract: Methods for setting mutually dependent parameters of a microprocessor controlled medical apparatus are disclosed. Mutually dependent parameters may be set by displaying mutually dependent parameter settings, displaying possible values for at least one parameter setting, whereby limits of the range of possible values is mutable and is automatically determined based on the current parameter settings, adjusting a parameter setting upon manual selection by an operator, automatically determining and displaying the value of at least one parameter setting depending on the parameter setting that is adjusted by the operator, whereby the determination of the dependent parameter setting is based on a stored relationship between parameter settings, implementing the set of adjusted parameter settings by actuating a batch setting acceptance operation, and operating the medical apparatus based on the set of adjusted parameter settings.

Abstract: An article and method to treat extracorporeally a patient's bodily fluid. The bodily fluid can include blood, cerebral spinal fluid and lymph. A first stage of the method includes applying a treatment. The treatment can comprise dosing with a medication, thermal treatment, or irradiation. The treatment can occur at levels that could otherwise compromise the patient's health. A second stage of the method substantially removes the treatment from the bodily fluid. The bodily fluid can then be returned to the patient. The article includes a treatment chamber that applies the treatment and a removal module for removing the treatment. The method can be a continuous process such as, for example, a dialysis process.

Abstract: Devices, systems, and methods are described herein for controlling or modulating the levels of one or more target components in the blood and/or lymph of a vertebrate subject. Devices and systems are provided that include a body defining at least one lumen configured for fluid flow; at least one controllable flow barrier to fluid flow into the at least one lumen; at least one first reservoir disposed within the body and configured to include one or more bifunctional tags, wherein the one or more bifunctional tags are configured to selectively bind to one or more target components in one or more of blood fluid or lymph fluid of a vertebrate subject; at least one treatment region disposed within the at least one lumen; and at least one second reservoir disposed in the at least one treatment region and configured to include one or more reactive components, wherein the one or more reactive components are configured to sequester the one or more bifunctional tags when bound to the one or more target components.

Abstract: Devices, systems, and methods are described herein for controlling or modulating the levels of one or more target components in the blood and/or lymph of a vertebrate subject. Devices and systems are provided that include a body defining at least one lumen configured for fluid flow; at least one controllable flow barrier to fluid flow into the at least one lumen; at least one first reservoir disposed within the body and configured to include one or more bifunctional tags, wherein the one or more bifunctional tags are configured to selectively bind to one or more target components in one or more of blood fluid or lymph fluid of a vertebrate subject; at least one treatment region disposed within the at least one lumen; and at least one second reservoir disposed in the at least one treatment region and configured to include one or more reactive components, wherein the one or more reactive components are configured to sequester the one or more bifunctional tags when bound to the one or more target components.

Abstract: A method for increasing the shelf life of donor blood contemplates the following steps. In the first step blood is transferred to a sterile container and mixed with an anticoagulant as indicated in step 20. The anticoagulant and donor blood are centrifuged in step 22 at about 4,000 rpm for about 15 minutes. After centrifuging the red blood cells are separated and placed in a sterile tube. In the next step the red blood cells are irradiated by a laser that emanates a wavelength of about 633 nm for a time period of about 24 hours. During rotation the RBCs are rotated to provide uniform exposure. Such laser biostimulation produces an enhancement of shelf life of donor blood by 66%.

Abstract: The present invention relates generally to the field of hemodialysis, including methods and kits that can be employed to improve hemodialysis therapy. The present invention encompasses methods and kits useful for reducing vascular access complications associated with hemodialysis therapy and prolonging the period of time for which a vascular access site can be used in a patient.

Abstract: Candidate cells, such as circulating tumor cells (CTCs), present with blood are captured using a multiple stage device, having successive stages configured to deviate candidate cells out of the blood while slowing down the flow rates of the deviated resultant for easier capture of CTCs through progressive stages. The devices can include separation channel and deviation channels formed of micro-post patterns dimensioned to deviate different desired candidate cells for analysis.

Abstract: The invention provides a way of producing a natural immunologically active state in a person by subjecting him to an apheresis procedure with bioincompatible biomaterials for about one hour. To safely control the immunological shock induced by this procedure, the person is put under general anesthesia for about six hours, including the apheresis time and at least an additional five hours thereafter. This immunological activation is useful for treating malignant tumors and diseases related to immunosuppression, such as AIDS. The invention also provides for the use of an apheresis column containing a blood perfusion filter with bioincompatible materials for treating malignant tumors and infectious diseases.

Abstract: This invention relates to a means of clearing out a cholesterol, calcium and plaque build-up resident to a living circulatory system, in addition to dissolving various kinds of blood clots, and removing other foreign matter, all by means of charged particle migration, through the application of an electromotive source.

Abstract: Treatment of carbon monoxide poisoning of a body by removal of a portion of the blood from the body, placing the portion in an exposure cell, exposing the portion in the cell to light of wave length and intensity that causes dissociation of carbon monoxide from hemoglobin, and returning the portion to the body. The intensity and wave length of the light is sufficient to dissociate a therapeutically-effective amount of carbon monoxide from the hemoglobin in the blood. The blood is circulated from and to the body through a concentric double lumen cannula. The wave lengths of the light are 540 and/or 570 nanometers. The cell exposes the blood to at least 9.5 Joules of dissociative light per milliliter of blood, and least 9.5 Watts of dissociative light per milliliter of blood per second. Oxygen is provided to, and the dissociated carbon monoxide is removed from the system.

Abstract: The present invention relates to a method for illuminating the viruses in a circulatory blood, comprising the following steps of: 1) Adding an anticoagulant into a whole blood source and establishing a circulation system for the whole blood source; 2) Withdrawing the whole blood with the anticoagulant into a plasma-separating device for a separation, when finished, directly pumping the red-blood cells back into the whole blood source and transporting the plasma into a mixing transport pump after the separation; 3) Meanwhile, pumping a photosensitizer methylene blue into the mixing transport pump so that the methylene blue is mixed with the plasma and pumped together into a plasma container; 4) Using an illumination device to illuminate the plasma in the plasma container for virus illumination, and pumping the virus-illuminated plasma into a removing device for removing off the photosensitizer; 5) The methylene blue being absorbed by the removing device and the plasma illuminated being transfused back into the

Abstract: An arteriovenous graft system is described. The arteriovenous graft system includes an arteriovenous graft that is well suited for use during hemodialysis. In order to minimize or prevent arterial steal, at least one valve device is positioned at the arterial end of the arteriovenous graft. In one embodiment, for instance, the arteriovenous graft system includes a first valve device positioned at the arterial end and a second valve device positioned at the venous end. In one embodiment, the valve devices may include an inflatable balloon that, when inflated, constricts and closes off the arteriovenous graft. If desired, a single actuator can be used to open and close both valve devices.

Abstract: An arteriovenous graft system is described. The arteriovenous graft system includes an arteriovenous graft that is well suited for use during hemodialysis. In order to minimize or prevent arterial steal, at least one valve device is positioned at the arterial end of the arteriovenous graft. In one embodiment, a subcutaneous arteriovenous graft system is described. The system includes an arteriovenous graft having an arterial end and an opposite venous end with a first valve device positioned at the arterial end of the arteriovenous graft and a second valve device positioned at the venous end of the arteriovenous graft. The system also includes an actuator having an accumulator. The actuator is in communication with both the first valve device and the second valve device and is configured to cause each valve device to open or close simultaneously. The accumulator assists in maintaining a generally constant pressure when the actuator causes each valve device to close.

Abstract: The invention is directed to the removal of serum gal-3 from circulation by plasmapheresis using gal-3 binding agents in either a fixed bed, or in a form easily removed, such as by being complexed with magnetic particles. This method, on its own, brings a sharp reduction and relief from the inflammation and fibroses that can be induced by circulating gal-3. The process may be combined with the administration of gal-3 binding agents, such as modified citrus pectin, to further lower unbound gal-3 levels, to the point where gal-3 in the tissues may be addressed. This method may also be combined with removal of TNF receptors to provide an effective treatment for cancer.

Abstract: The present invention is directed to a method for removing cytokines and/or pathogens from blood or blood serum (blood) by contacting the blood with a solid, essentially non micro-porous substrate which has been surface treated with heparin, heparan sulfate and/or other molecules or chemical groups (the adsorbent media or media) having a binding affinity for the cytokine or pathogen(s) to be removed (the adsorbates), and wherein the size of the interstitial channels within said media is balanced with the amount of media surface area and the surface concentration of binding sites on the media in order to provide adequate adsorptive capacity while also allowing relatively high flow rates of blood through the adsorbent media.

Abstract: Provided are a method of conveniently and efficiently removing abnormal prion protein from a blood product and a method of removing leukocyte simultaneously with abnormal prion protein. The method of removing an abnormal prion protein from a blood product includes filtering the blood product through a filter filled with a carrier coated with a polymer, which is composed of three units including 20 mol % or more and 40 mol % or less of a unit originating from a hydrophobic polymerizable monomer, 5 mol % or more and 13 mol % or less of a unit originating from a polymerizable monomer containing a basic nitrogen-containing part, and a unit originating from a polymerizable monomer containing a protonic neutral hydrophilic part as the balance, and then recovering the filtered blood product.

Abstract: The interface between nanotechnology and biological systems is used to synthetically replicate the body's vital, innate, immune functions with targeted precision. Through the creation and use of complexed nanodiamonds (or other particles) with capture agents in a flow-through return apparatus or in an analytic/diagnostic tool, the invention provides individualized treatment of blood-borne pathogens and disease spectrums and rapid, individualized diagnostics. The invention can be used, for example, to clear blood-borne pathogens during initial infections prior to tissue sequestration in real time, to decrease overwhelming numbers of bacterial/viral/cytokine load during life threatening infectious conditions, to super sensitize the immune system to a variety of conditions-cancer markers, vaccinates, etc.

Abstract: Methods for treating malaria are provided, the treatment comprising the step of removing malaria-infected red blood cells from the patient's blood. Blood is drawn from the patient's circulatory system and circulated through a blood purification device that selectively eliminates the infected red blood cells from all other blood's components and replaces the cleansed blood back into the patient's circulatory system. A blood purification device, which is useful to perform the therapeutic methods of the invention, is also provided. The device leverages the magnetic properties of the hemozoin contained within the infected red blood cells and comprises one or more separation chambers (4) though which blood flows through a high-gradient magnetic field generated by an array of wires (5) separated from the chambers and not in contact with the patient blood.

Abstract: The invention provides an apparatus for use in the treatment of an individual suffering from liver disease, including: (a) means for selectively removing albumin from the blood of the individual; and (b) means for selectively removing endotoxin from the blood of the individual.

Abstract: An extracorporeal blood processing method using a blood circuit comprising a pair of blood passages attached to opposite flow ends of a blood treatment device and said blood circuit is mounted on a blood pump console, the method includes: withdrawing blood from a vascular system of a human patient and drawing the blood into the blood circuit; pumping the withdrawn blood through one of the pair of blood passages using a first blood pump of the console and into the blood treatment device; pumping the treated blood from the treatment device through the other of the pair of blood passages using a second blood pump of the console; infusing the treated blood from the other blood passage and into the vascular system of the patient, and periodically reversing a flow direction of blood through the pair of blood passages and blood treatment device.

Abstract: A circuit for collecting a blood component includes a blood collection device provided with a blood collection needle through which blood is collected from a blood donor, a blood separator in which the blood collected by the above blood collection device is separated, a blood component collection bag in which a predetermined blood component separated by the above blood separator is collected, a blood line in which the blood collection needle is connected to an inlet of the blood separator, a line for removing an initial blood flow, which branches from a first branching portion formed in the blood line, and in which an initial flow of blood collected from the blood donor is removed, and an anticoagulant-injection line that branches from a second branching portion, formed in the line for removing the initial blood flow, and into which an anticoagulant is injected.

Abstract: Shock waves are applied to clean and sterilize fluids in containers and conveyances. Shock waves destroy pathogens and pollutants in blood, water, food liquids and other fluids.

Abstract: A method to treat cancer uses ultrapheresis, refined to remove compounds of less than 120,000 daltons molecular weight, followed by administration of replacement fluid, to stimulate the patient's immune system to attack solid tumors. In the preferred embodiment, the patient is ultrapheresed using a capillary tube ultrafilter having a pore size of 0.02 to 0.05 microns, with a molecular weight cutoff of 120,000 daltons, sufficient to filter one blood volume. The preferred replacement fluid is ultrapheresed normal plasma. The patient is preferably treated daily for three weeks, diagnostic tests conducted to verify that there has been shrinkage of the tumors, then the treatment regime is repeated. The treatment is preferably combined with an alternative therapy, for example, treatment with an anti-angiogenic compound, one or more cytokines such as TNF, gamma interferon, or IL-2, or a procoagulant compound. The treatment increases endogenous, local levels of cytokines, such as TNF.

Abstract: A method for batch implementation of settings in a renal replacement therapy device including: displaying on a user interface control settings which may be manually selected by an operator; selecting an independent control setting of the plurality of control settings; adjusting the independent control setting to an independent control setting level selected by an operator; temporarily storing the adjusted independent control setting level; automatically adjusting a dependent control setting level based upon the independent control level; displaying the adjusted independent control setting level and the adjusted dependent control setting, and implementing both the adjusted independent control setting level and the adjusted dependent control setting to control the device, by actuating a batch setting acceptance operation.

Abstract: Methods and devices are provided for the extracorporeal ablation of target cells circulating in blood of an organism. Exogenous material introduced into the blood preferentially associates with target cells (e.g. cancer cells, bacteria, viruses) in the blood. An extracorporeal continuous flow pathway accesses the patient's blood to apply an external energy source to the blood at an ex vivo ablation device in a portion of the extracorporeal continuous flow pathway. The exogenous material interact with the applied energy so as to result in the damage or death of the target cells. The blood is then returned to the body in a continuous-flow pattern. By applying the energy while the blood is in the ex vivo ablation device, shielding of the target cells by the body is reduced and detrimental effects on the organs and tissues of the body are avoided or mitigated.

Abstract: A HIV filtration machine and method of filtration using the machine and method of detecting HIV, the said machine comprising an acrylic cylindrical tube divided into three portions i.e. needle portion (2), barrel portion (10), and tray (16), characterized in that the needle portion consists of three needle points (3, 4, 5), the said needle points are detachably connected with three blood carrying tubes (27, 28, 29) serially fixed into barrel portion, a valve (12) is provided at the end point of said blood carrying tubes, a piston (9) is detachably fixed above the plunger (22) and connected with a spring for creating movement of the plunger towards the tray, the said tray is one inch or less diameter in round shape and connected with steel ring of filter (14) and is connected with chip and micro camera, for data transmission to the remote computer or mobile device, the said filter having less than 1 micron to more than 8.5 micron.

Abstract: Methods and devices for selectively removing from a subject a target cell, pathogen, or virus expressing a binding partner on its surface are presented. In one embodiment, the device contains an excorporeal circuit, which includes, at least, a magnetic filter comprising a magnet and a removable, magnetizable substrate capable of capturing magnetic nanomaterials; and a pump in fluid communication with the magnetic filter, wherein the pump moves fluid through the excorporeal circuit. The magnet is capable of generating a magnetic field sufficient to capture magnetic nanomaterials in the magnetic field. In a preferred embodiment, the target cells are cancer cells and/or cells infected with pathogenic agents. The devices may be designed for extracorporeal or in vivo uses. Functionalized superparamagnetic nanoparticles are either mixed ex vivo with a biological fluid from the patient or injected into the patient.

Abstract: An extracorporeal fluid treatment apparatus includes a separator comprising a cartridge surrounding a porous separation membrane. The membrane separates a main flow path of a cellular component of the blood from a plasma flow path. An affinity medium is disposed within the plasma flow path to bind contaminants such as viral pathogens or toxins contained within the plasma. A pump pumps the plasma through the affinity medium at an assisted flow rate preferably between 10% and 40% of the whole blood flow rate. The assisted flow rate is selected to reduce a T90% of the apparatus by at least 50% as compared to a T90% of the apparatus without the plasma pump. A method of treating blood containing contaminants includes supplying infected blood to a separator and pumping the plasma component through an affinity medium at an assisted flow rate to increase contaminant clearance.

Abstract: In a peritoneal dialysis embodiment of the present invention, spent dialysate from the patient's peritoneal cavity passes, along a patient loop, through a dialyzer having a membrane that separates waste components from the spent dialysate, wherein the patient loop returns fresh dialysate to the patient's peritoneal cavity. The waste components are carried away in a second regeneration loop to a regeneration unit or sorbent cartridge, which absorbs the waste components. The regeneration unit removes undesirable components in the dialysate that were removed from the patient loop by the dialyzer, for example, excess water (ultrafiltrate or UF), toxins and metabolic wastes. Desirable components can be added to the dialysate by the system, such as glucose and electrolytes. The additives assist in maintaining the proper osmotic gradients in the patient to perform dialysis and provide the necessary compounds to the patient.

Abstract: Methods for treating malaria are provided, the treatment comprising the step of removing malaria-infected red blood cells from the patient s blood. Blood is drawn from the patient s circulatory system and circulated through a blood purification device that selectively eliminates the infected red blood cells from all other blood s components and replaces the cleansed blood back into the patient s circulatory system. A blood purification device, which is useful to perform the therapeutic methods of the invention, is also provided. The device leverages the magnetic properties of the hemozoin contained within the infected red blood cells and comprises one or more separation chambers (4) though which blood flows through a high-gradient magnetic field generated by an array of wires (5) separated from the chambers and not in contact with the patient blood.

Abstract: A system and method of utilizing microbubbles and liposomes as viral sequestering agents. Microbubbles and liposomes having polyanions and conjugation systems are injected into the bloodstream of a subject human or animal. The microbubbles and/or liposomes attract virus particles including envelope viruses. After the microbubbles and/or liposomes have circulated in the blood for a pre-established time period, the microbubbles and/or liposomes along with attached virus particles are separated from the blood of the subject by passing the blood over or through a substrate or using a centrifuge. The substrate includes a conjugation system which has an affinity for the polyanions of the microbubbles and/or liposomes. As the microbubbles and/or liposomes and attached virus particles are removed from the blood, the viral titer of the subject is lowered.

Abstract: It is an object of the present invention to provide a practically applicable substrate for blood treatment for specifically capturing a target substance such as a cell directly from the whole blood, and an inexpensively and industrially applicable substrate for biological fluid treatment which is capable of separating a target substance directly from a biological fluid. The present invention provides a substrate for biological fluid treatment in which a recognition molecule having a selective binding property for a target substance is covalently immobilized on a surface of the substrate, wherein the recognition molecule is a linear molecule comprising a ligand moiety and an association domain, and at least four or more recognition molecules form an assembly structure.

Abstract: Devices and methods for treating, preventing from growth, and neutralizing hyperproliferative, undifferentiated, or virally infected cells in a liquid medium using high-frequency, low-energy ultrasound.

Abstract: Provided herein is an innovative hemoperfusion system and method including a thermal-fused broad-spectrum biocidal iodinated interactive polymer for the treatment of biological contaminants in body fluids. In one exemplary embodiment, the system and method utilizes a Triosyn® thermal fused broad-spectrum iodinated interactive polymer, included in a hemoperfusion column, for devitalizing high levels of cell-free microorganisms in whole blood and biological fluids in relation with the characterization of blood cells viability and function post-treatment.

Abstract: The Human Immunodeficiency Virus posses a significant threat to the world's population. Current strategies have not been adequate to contain and eradicate this deadly viral infection. HIV utilizes a T-Helper cell as a host to generate replicas of itself. Reversing HIV's own biologically deadly tactics and developing blood filtering techniques that incorporate filter mediums that engage the cell-surface receptors uniquely located on the surface of a T-Helper cell infected with the HIV genome can lead to terminating the infected T-Helper cells. Filter mediums possessing cell-surface receptors intended to terminate infected T-Helper cells by triggering apoptosis, is an effective means to eliminate HIV's host cells and thus provides a valuable strategy to prevent and treat AIDS. Similar techniques can be utilized to terminate other types of cells that act as hosts for pathogens as well as terminating cancer cells.

Abstract: The Human Immunodeficiency Virus posses a significant threat to the world's population. Current strategies utilized to treat infectious agents have not been adequate to contain and eradicate this deadly viral infection. HIV seeks out its host, a T-Helper cell, by utilizing glycoprotein 120 probes to engage a CD4 cell-surface receptor located on the surface of a T-Helper cell. Developing blood filtering techniques that incorporate filter mediums that offer HIV virion's probes the opportunity to engage the cell-surface receptors they are seeking offers a means of neutralizing and removing HIV. Filtering the blood of a patient with filter mediums comprised of T-Helper cells, sheets of lipid bilayer or virus-like structures with each type of medium possessing cell-surface receptors intended to attract and engage HIV virions provides an effective strategy to prevent and treat AIDS.

Abstract: A device for removing bacterial lipopolysaccharides and lipoteichoic acids from blood or plasma in an extracorporeal perfusion system contains, in a housing that can be incorporated into the perfusion system, a hollow fiber material that is suitable for the selective removal of bacterial lipopolysaccharides and lipoteichoic acids, the device being arranged in such a way that the blood or plasma entering through a first opening of the housing must pass through the hollow fiber material before it leaves through a second opening of the housing and is directed to the rest of the perfusion circuit.

Abstract: A blood purification device has a blood purification element divided into two chambers by a semipermeable membrane, with a first chamber as part of a dialysis fluid loop and a second chamber as part of an extracorporeal blood loop. By virtue of an analysis unit operatively connected to a sensor in the dialysis fluid loop, the device provides simple and uncomplicated determination of the blood purification performance of the blood purification element for a second material by derivation from a previously established blood purification performance for a first material. In this way, the device also determines the blood concentration of the second material during the blood treatment through measurements in the dialysis fluid without intervention in the treatment sequence.

Abstract: A system for removing undesirable material from vessels and from chambers within the heart is provided. The system includes a suction cannula for removing the undesirable material from a site of interest within a patient. A filter device may be provided for capturing the undesirable material and removing it from the fluid flow. The system also includes pump for generating the necessary suction force through the suction cannula to dislodge the undesirable material from the site of interest and for generating a sufficient driving force to direct the fluid flow downstream within the system. The system further includes a reinfusion cannula for introducing fluid removed from the site of interest back into a patient. A method for removing undesirable material from vessels and from heart chambers is also provided.

Abstract: Methods and devices are provided for the extracorporeal ablation of target cells circulating in blood of an organism. Exogenous material introduced into the blood preferentially associates with target cells (e.g. cancer cells, bacteria, viruses) in the blood. An extracorporeal continuous flow pathway accesses the patient's blood to apply an external energy source to the blood at an ex vivo ablation device in a portion of the extracorporeal continuous flow pathway. The exogenous material interact with the applied energy so as to result in the damage or death of the target cells. The blood is then returned to the body in a continuous-flow pattern. By applying the energy while the blood is in the ex vivo ablation device, shielding of the target cells by the body is reduced and detrimental effects on the organs and tissues of the body are avoided or mitigated.

Abstract: The present invention provides compositions and methods for detecting, treating, and preventing microbial infection, especially infection caused by Bacillus anthracis (“anthrax”).

Abstract: The present invention regards the use of hemofilters for the removal of bacterial toxins (lipopolysaccharides) from the blood, said hemofilters comprising a solid support to which cyclodextrins are covalently bonded. The solid support can be a fabric or non-woven fabric or a polymeric resin obtained by means of cross-linking of the cyclodextrins with appropriate cross-linking agents, for example epichlorohydrin.

Abstract: A method of immunomodulation by contacting the bodily fluid of a patient with renal tubule cells outside of the kidney.